Alembic Pharmaceuticals Limited (APLLTD) reports strong Q2 FY27 performance with revenue up 36% and PAT up 81% YoY.
Dr. Lal Path Labs Ltd. (LALPATHLAB) reports a 19.6% revenue growth and 27.5% PAT increase in Q2 FY27.
Marksans Pharma Limited (MARKSANS) reports record Q2 & H1 FY27 results with revenue crossing ₹900 crore and PAT nearly doubling.
Biocon Limited (BIOCON) reports Q2FY27 total income at Rs 4,423 Cr, up 1% YoY. Biopharma revenue up 5%.
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reports Q2 FY27 growth, driven by portfolio transformation and innovation.
Zydus Lifesciences Limited (ZYDUSLIFE) reports a 29% YoY revenue surge in Q2 FY27, driven by strong performance across its segments.
Amanta Healthcare Limited (AMANTA) announces Q2 & H1FY27 results with revenue up 17% YoY, PAT growth at 26%, and new capacity expansions.
Lupin Limited reported Q2 FY2027 results with sales up 14% YoY, but PAT down 22%. Key highlights include strong growth in key markets.
Vijaya Diagnostic Centre Limited (NSE: VIJAYA) reports Q2 & H1 FY27 results with 26.7% YoY revenue growth, driven by strong operational performance.
Laxmi Dental Limited (LAXMIDENTL) reports Q2 FY27 results with a 10% revenue increase, strong EBITDA and PAT margins.